chr16-20460269-A-C
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM2PP3_Moderate
The NM_001308172.2(ACSM2A):c.155A>C(p.Asp52Ala) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: not found (cov: 30)
Consequence
ACSM2A
NM_001308172.2 missense
NM_001308172.2 missense
Scores
4
10
5
Clinical Significance
Conservation
PhyloP100: 3.75
Genes affected
ACSM2A (HGNC:32017): (acyl-CoA synthetase medium chain family member 2A) This gene encodes a mitochondrial acyl-coenzyme A synthetase that is specific for medium chain fatty acids. These enzymes catalyze fatty acid activation, the first step of fatty acid metabolism, through the transfer of acyl-CoA. These enzymes also participate in the glycine conjugation pathway in the detoxification of xenobiotics such as benzoate and ibuprofen. Expression levels of this gene in the kidney may be correlated with kidney function. This gene and its paralog ACSM2B (Gene ID: 348158), both present on chromosome 16, likely arose from a chromosomal duplication event. [provided by RefSeq, May 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 4 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.846
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ACSM2A | NM_001308172.2 | c.155A>C | p.Asp52Ala | missense_variant | 2/14 | ENST00000573854.6 | NP_001295101.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ACSM2A | ENST00000573854.6 | c.155A>C | p.Asp52Ala | missense_variant | 2/14 | 1 | NM_001308172.2 | ENSP00000459451.1 |
Frequencies
GnomAD3 genomes Cov.: 30
GnomAD3 genomes
Cov.:
30
GnomAD4 exome Cov.: 33
GnomAD4 exome
Cov.:
33
GnomAD4 genome Cov.: 30
GnomAD4 genome
Cov.:
30
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 15, 2023 | The c.155A>C (p.D52A) alteration is located in exon 3 (coding exon 1) of the ACSM2A gene. This alteration results from a A to C substitution at nucleotide position 155, causing the aspartic acid (D) at amino acid position 52 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T;T;T;T;T;T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;.;.;.;D;D
M_CAP
Benign
D
MetaRNN
Pathogenic
D;D;D;D;D;D
MetaSVM
Benign
T
MutationAssessor
Pathogenic
.;M;M;M;.;M
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
.;.;D;.;.;D
REVEL
Uncertain
Sift
Uncertain
.;.;D;.;.;D
Sift4G
Uncertain
D;D;D;D;D;D
Polyphen
1.0
.;D;D;D;.;D
Vest4
0.78, 0.78, 0.75
MutPred
Loss of catalytic residue at D52 (P = 0.0281);Loss of catalytic residue at D52 (P = 0.0281);Loss of catalytic residue at D52 (P = 0.0281);Loss of catalytic residue at D52 (P = 0.0281);Loss of catalytic residue at D52 (P = 0.0281);Loss of catalytic residue at D52 (P = 0.0281);
MVP
MPC
1.0
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at